COMMUNIQUÉS West-GlobeNewswire

Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting
19/10/2026
- FDA approves IDE supplement expanding REGAIN from 10 to 20 patients, with additional study endpoints and interim analysis - - Abstract authored by REGAIN study principal investigator Dr. Joshua Palmer of The Ohio [...]
J-Star Holding Co., Ltd. Advances U.S. Drone Manufacturing Initiative; Negotiates Acquisition of Facility in the Greater Houston Area
19/10/2026
Company is Organizing an Independent Texas-based Manufacturing Platform, Contributing Proprietary Composite Technology and Engineering Expertise to Support Planned U.S. Drone-Frame Production Strategic Real Estate [...]
Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
19/10/2026
CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]
Indivior to Report Third Quarter 2026 Financial Results
19/10/2026
RICHMOND, Va., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its third quarter 2026 financial results on Thursday, October 29, 2026. The results will [...]
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026
19/10/2026
ROCKVILLE, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
19/10/2026
In advance of November 10, 2026 GDUFA goal date, three commercial lots of Preservative-Free Ketamine have been successfully manufactured in compliance with “Process Validation” required under FDA “Good Manufacturing [...]
Fangzhou and Cutia Therapeutics Partner to Advance AI-Powered Dermatology and Chronic Health Management
19/10/2026
GUANGZHOU, China, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, announced a strategic partnership with Cutia [...]
SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications
19/10/2026
TEL AVIV, Israel, Oct. 19, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), announced that it will shift its strategic focus toward Agentic AI-powered technologies, including [...]
OneMedNet Signs Global Pharmaceutical Intelligence Provider as Channel Partner, Extending Reach in Pharma Market
19/10/2026
Agreement with a leading global provider of pharmaceutical intelligence and data solutions expands distribution of OneMedNet’s first-party, direct-from-source multimodal Real-World Data; Strengthening its presence in a [...]
Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
19/10/2026
Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 Congress Data supplements unprecedented two-year data from the trial including a 75% Objective Response [...]
Prime Minister Mark Carney Sends Greetings as Canada Lights Up Sea-foam Green for International Stuttering Awareness Day
19/10/2026
From Niagara Falls to the CN Tower, landmarks across Canada will shine sea-foam green on October 22 as Canadians call for greater understanding and acceptance of stuttering. TORONTO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
19/10/2026
COPENHAGEN, Denmark, October 19, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount [...]
Transactions under Novonesis’ share buyback program
19/10/2026
Please read the announcement in PDF Attachment 2026_22_Share_buyback
IBA lance NEPTIS® Perform Duo, un module de synthèse unique pour le développement de traceurs et leur production de routine
19/10/2026
Premier nouveau produit lancé par ORA depuis son acquisition par IBA en décembre 2025. Louvain-la-Neuve, Belgique, 19 octobre 2026 à 7h00 – IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’ [...]
IBA launches NEPTIS® Perform Duo, one synthesizer module from tracer development to routine production
19/10/2026
First new product from ORA, since IBA acquired ORA in December 2025 Louvain-la-Neuve, Belgium – October 19, 2026 7 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology [...]
JJP Biologics Doses the First Patients in Phase 1b Clinical Trial of Nebaprubart in Rheumatoid Arthritis (RA)
19/10/2026
Expansion of nebaprubart (JJP-1212) into RA follows positive interim data from its ongoing Phase 1b trial in linear IgA dermatosis (LAD), marking the second indication for the Company’s lead asset and expanding clinical [...]
Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830
19/10/2026
Press release – No. 21 / 2026 Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830 ZP9830 is a novel Kv1.3 ion channel blocker [...]
Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio
19/10/2026
Phase III Krascendo 1 results demonstrated divarasib’s superiority over current standard of care, first-generation KRAS G12C inhibitors in previously treated advanced G12C-mutated non-small cell lung cancer Patient- [...]
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
19/10/2026
Collaboration establishes a framework for a dedicated U.S. source of astatine-211 ( 211 At), a scarce, next-generation alpha-emitting isotope with significant potential in targeted alpha therapy (TAT). Secures long-term [...]

Pages